Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.

Autor: Jagirdar K; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Portuallo ME; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Wei M; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Wilhide M; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Bravo Narula JA; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Robertson BM; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Alicea GM; Department of Chemical and Biomolecular Engineering, The Johns Hopkins Whiting School of Engineering, Baltimore, MD, USA., Aguh C; Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Xiao M; The Wistar Institute, Molecular and Cellular Oncogenesis Program and Melanoma Research Center, Philadelphia, PA, USA., Godok T; The Wistar Institute, Molecular and Cellular Oncogenesis Program and Melanoma Research Center, Philadelphia, PA, USA., Fingerman D; The Wistar Institute, Molecular and Cellular Oncogenesis Program and Melanoma Research Center, Philadelphia, PA, USA., Brown GS; The Wistar Institute, Molecular and Cellular Oncogenesis Program and Melanoma Research Center, Philadelphia, PA, USA., Herlyn M; The Wistar Institute, Molecular and Cellular Oncogenesis Program and Melanoma Research Center, Philadelphia, PA, USA., Elad VM; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Guo X; Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Toska E; Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Zabransky DJ; Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Wubbenhorst B; Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Nathanson KL; Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA., Kwatra S; Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA., Goyal Y; Department of Cell and Developmental Biology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA., Ji H; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Liu Q; The Wistar Institute, Molecular and Cellular Oncogenesis Program and Melanoma Research Center, Philadelphia, PA, USA., Rebecca VW; Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. vrebecc2@jh.edu.; Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. vrebecc2@jh.edu.

Publikováno v: Oncogene [Oncogene] 2024 Feb; Vol. 43 (6), pp. 395-405. Date of Electronic Publication: 2023 Dec 08.

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas.

Autor: Rebecca VW; The Wistar Institute, Philadelphia, PA, USA.; Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Xiao M; The Wistar Institute, Philadelphia, PA, USA., Kossenkov A; The Wistar Institute, Philadelphia, PA, USA., Godok T; The Wistar Institute, Philadelphia, PA, USA., Brown GS; The Wistar Institute, Philadelphia, PA, USA., Fingerman D; The Wistar Institute, Philadelphia, PA, USA., Alicea GM; The Wistar Institute, Philadelphia, PA, USA.; Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Wei M; Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Ji H; Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Bravo J; Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Chen Y; The Wistar Institute, Philadelphia, PA, USA., Fane ME; The Wistar Institute, Philadelphia, PA, USA.; Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA., Villanueva J; The Wistar Institute, Philadelphia, PA, USA., Nathanson K; University of Pennsylvania, Philadelphia, PA, USA., Liu Q; The Wistar Institute, Philadelphia, PA, USA., Gopal YNV; M.D. Anderson Cancer Center, TX, USA., Davies MA; M.D. Anderson Cancer Center, TX, USA., Herlyn M; The Wistar Institute, Philadelphia, PA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2023 Jan 21. Date of Electronic Publication: 2023 Jan 21.